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Abstract
Objectives: To investigate the duration of sequential HAART regimens and predictors of first-line regimen discontinuation
among HIV-1 vertically infected children and adolescents.
Design: Multicentre survey of antiretroviral-naı¨ve patients enrolled in the HIV-Paediatric Cohor,t CoRISpeS-Madrid Cohort,
Spain.
Methods: Patients with a follow-up of $1 month spent on HAART, with available baseline CD4 count and HIV-viral load (VL)
were included. Time spent on sequential HAART regimens was estimated and multivariable regression was used to identify
predictors of time to first-line regimen discontinuation.
Results: 104 patients were followed for a median 8 years after starting HAART among 1996–2012; baseline %CD4 was 21.5
(12.3–34.0)and viral load was 5.1 (4.6–5.6) log10 copies/mL. Patients received a mean of 1.9 regimens. Median time on first-
line HAART (n = 104) was 64.5 months; second HAART (n = 56) 69.8 months; and third HAART (n = 21) 66.5 months. Eleven
(11%) patients were lost to follow-up while on first-line HAART and 54% discontinued (cumulative incidence of 16% and
38% by 1 and 3-year, respectively). The main predictor of first-line regimen discontinuation was suboptimal adherence to
antiretrovirals (AHR: 2.60; 95% CI: 1.44–4.70).
Conclusions: Adherence to therapy was the main determinant of the duration of the first-line HAART regimen in children. It
is important to identify patients at high risk for non-adherence, such as very young children and adolescents, in provide
special care and support to those patients.
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Introduction
The introduction of highly active antiretroviral therapy
(HAART) to medical care for vertically HIV-1-infected children
has increased life expectancy and resulted in a substantial decline
in AIDS incidence [1–8]. However, the paucity of antiretroviral
choices and the survival to adolescence and adulthood of HIV-1-
infected children pose main concerns about HAART effectiveness.
Worldwide, there is a growing cohort of adolescents who are long-
term survivors of vertically-acquired HIV-1 infection, who are
likely to modifying the shape of the HIV epidemic in the next
future. Being these patients heavily HAART-experienced and
facing developmental problems, these patients are characterised by
unique features which may hamper the impact of HAART. In
particular, the duration of first-line HAART is critical in the
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context of the lifelong treatment of these patients. Several factors
that have been shown to limit the success of HAART in children
are the patient characteristics [9], lack of adherence [10,11], lack
of appropriate dosing [12,13], drug tolerability and toxicity [14–
16], and viral resistance [17]. In Spain, a free access to HAART
has been universal since 1996, leading to a dramatic decrease of
AIDS and mortality [18]. Nonetheless, prevalence in Spain is still
one of the highest HIV-1 epidemic in Western Europe [19].
Within Spain, the Comunidad Auto´noma de Madrid accounted for the
26% of the AIDS cases associated to HIV-1 vertical transmission,
most of them now, older children [20].
In this study, we evaluate the determinants of first-line HAART
discontinuation in a large cohort of HIV-1-infected paediatric
patients from Madrid, Spain. The findings of this study provide
valuable information for the management of paediatric HIV-1-
infection.
Paediatric Patients and Methods
Ethics Statement
The study was conducted according to the Declaration of
Helsinki and was approved by the Ethical Committees of each
participating hospital of the HIV Paediatric Cohort (CoRISpeS-
Madrid Cohort) working group. Written informed consent was
obtained from all parents or tutors.
The HIV Paediatric Cohort of the Comunidad Auto´noma
de Madrid
The HIV Paediatric Cohort of the Comunidad Auto´noma de Madrid
(CoRISpeS-Madrid Cohort) was established in 1995 as an open
cohort of all HIV-1 vertically-infected children identified in a
multicentre network of referral paediatric hospitals based in the
Comunidad Auto´noma de Madrid (see Annex). HIV-1 vertical
transmission was assumed to have occurred on the date of birth
[21]. Children were enrolled from 1982 (birth date of the first case
of HIV-1 vertical transmission in Madrid) to the present and were
monitored through active follow-up every 3–6 months according
to published guidelines [22]. In this cohort, children infected
before 1995 were enrolled retrospectively while children infected
after 1995 were enrolled prospectively. Complete ascertainment of
all records was carefully sought and cross-check with the National
AIDS Reports was performed. The cohort included 491 HIV-1
infected children and adolescents as of December 2012.
The present survey was conducted according to the Declaration
of Helsinki with the approval of the Institutional Ethics
Committee. Patients were selected retrospectively for this survey
and were eligible if they had no history of antiretroviral treatment
when they initiated their first HAART regimen. The other eligible
criteria were: a follow-up of $1 month spent on HAART;
available baseline CD4 count and HIV-1 RNA viral load (VL).
The study period for inclusion of patients was from 1996 to 2012.
Individuals were followed from the date of HAART initiation until
the date of death, or date of last visit in case of lost to follow-up, or
December 31, 2012 (administrative censoring date), which ever
occurred first. VL was measured by Amplicor Monitor assay
(Roche, Brandenburg, NJ) with a detection limit 50 copies/mL.
Several biological samples were provided by the HIV HGM
BioBank [23].
Demographics, clinical, immunological and virological data and
HAART use were gathered retrospectively. Clinical classification
of AIDS-defining events was based on international guidelines
[24,25]. All patients included in the study were eligible for
HAART initiation (i.e., any combination of $3 antiretrovirals,
excluding antiretroviral prophylaxis) [26]. A HAART regimen was
counted when it had been administered for at least 30 days (to
ensure that patients were genuinely taking their antiretrovirals). A
regimen discontinuation was defined as changing $2 antiretrovi-
rals simultaneously while continuing on HAART or an interrup-
tion of .30 days. Causes of initial HAART discontinuation were
extracted from medical charts, confirmed with paediatricians, and
classified as poor adherence, treatment failure, toxicity, simplifi-
cation, planned treatment interruption, decision of patient/
parents/tutor, social/family problem, death. Baseline laboratory
values were measured at the time of first regimen initiation (range:
26 months; +14 days). Laboratory values at regimen discontin-
uation were determined using the same window around the
discontinuation date. Calendar period for HAART initiation
(divided into 1996–2001 and 2002–2012) was categorised a priori,
because approval of lopinavir/ritonavir could have led to change
in treatment management [27–29]. Clinicians monitored adher-
ence by pill count and interviewing parents or tutors at each visit
during follow-up. Adherence was summarized as a single
percentage for each HAART regimen for each patient and
categorized as poor (,70%), intermediate (70–90%), good (91%–
99%), perfect (100%). Lost to follow-up was defined as no
communication between the patient and the clinic staff resulting in
missing at least 3 visits.
Statistical Analysis
Demographic and baseline characteristics and antiretroviral
therapy use are presented using descriptive statistics. The primary
endpoint was the time spent on sequential regimens and was
estimated by Kaplan-Meier analysis with exact 95% confidence
intervals (CI); log-rank test was used to compare survival curves.
Time was calculated from the date of HAART initiation until the
date of HAART change, or last visit in case of lost to follow-up, or
December 31, 2012 (administrative censoring date), whichever
occurred first. Univariate proportional hazards regression analyses
were performed to identify factors associated with first-line
regimen discontinuation, and multivariable proportional hazards
regression analysis was performed that included all factors for
which the results of univariate analysis were statistically significant
(P,0.05) or close to the margin of statistical significance. The
variables examined included demographic characteristics, social
indicators, baseline laboratory values, HIV-1 subtype, clinical
status, provision of antiretroviral prophylaxis to the paediatric
patients and calendar period for HAART initiation.
To ensure that outcome events could be correctly attributable to
the type of regimen, when a substitution of a single drug caused
the change from a protease inhibitor (PI)-based to a non-
nucleoside reverse transcriptase (NNRTI)-base regimen or vice
versa, the type of regimen was re-categorised on the basis of the
longest regimen for each patient. Analyses were performed by
using SPSS (v.19; Chicago, IL) and 2-tailed P-values ,0.05 were
considered statistically significant.
Results
Of 124 antiretroviral-naı¨ve children who started HAART, 104
were eligible. They initiated HAART between 1997–2012 and
had a median time of observation of 101.0 (51.9–139.8) months.
At baseline, the majority of children (56/104; 53.8%) had VL .
100.000 copies/mL and %CD4,25 (65/104; 62.5%). Other
baseline characteristics are listed in Table S1 in File S1.
Remarkably, a tendency to a better adherence among median
aged-children (2–12 years old) than among very young children (#
2 years old) and adolescents (.12 years old) was observed, with P-
value close to the margin of statistical significance (P = 0.063).
HAART Duration in HIV-1-Infected Children
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Overall, a rapid and sustained increase in median %CD4 and
concurrent decrease in %CD8 and VL was observed during
follow-up (Figure S1A in File S1). A comparative analysis among
patients included (n = 104) and not included (n = 20) in the survey
showed that the two groups were similar in the following
characteristics: demographics, clinical status, breastfeeding, ma-
ternal transmission category and age at HAART initiation (Table
S2 in File S1).
Antiretroviral Therapy Duration
Overall, the mean number of HAART regimens used was 1.9.
Eleven (10.6%) children were lost to follow-up while on first-line
HAART, 56/104 (53.8%) discontinued their initial regimen, one
(1.0%) died of dideoxynucleoside-induced severe lactic acidosis
and 36/104 (34.6%) remained under their first-line therapy. Of
those, 10/36 (27.8%) had a single-drug substitution within the
same class and 2/36 (5.6%) had a class change. Comparison with
initial HAART regimen to successive regimens revealed that fewer
salvage regimens based on a single PI and more with a boosted PI
or four drugs were used (Table S1 in File S1). After 2007, when
nelfinavir was withdrawn from the European market, there was a
considerable increase in the use of lopinavir/ritonavir (Figure S1B
in File S1). Median time on first-line regimen was 64.5 months
(47.5–81.5), similar to time spent on second and third-line
regimens (Table S1 in File S1; Figure 1A). Treatment failure
was the main cause of first-line therapy discontinuation (19/57,
33.3%), followed by poor adherence (12/57, 21.1%) and
simplification (10/57, 17.5%) (Table S3 in File S1). Time spent
receiving first-line HAART was shorter among individuals with
poor adherence to antiretrovirals than among those with good/
perfect adherence (33.5 months vs 92.2; P = 0.001) and among
those with intermediate adherence than among those with good/
perfect adherence (22.5 months vs 92.2; P,0.001; Figure 1B).
This result was confirmed by multivariable analysis in which
confounders such as age and sex were controlled (Table 1).
Discussion
The availability of HAART has transformed the HIV-1
infection into a chronic and treatable disease. As perinatally-
infected children likely require life-long treatment, the assessment
of the duration of initial and successive HAART regimens is
crucial. This study evaluated the duration of initial and successive
HAART regimens and the predictors of therapy discontinuation
in HIV-1-infected children of CoRISpeS-Madrid Cohort from
1996 up to 2012. This cohort is highly representative of the
paediatric HIV-1 community throughout the Comunidad Auto´noma
de Madrid (Spain) as it includes all the cases of vertical HIV-1
transmission that occurred in this area since the dawn of the
epidemic in 1982 [30]. Among 104 subjects with median follow-up
of 8 years, the 54% discontinued initial HAART with a cumulative
incidence of 16% and 38% by 1 and 3-year, respectively. Along
with a sustained immunovirological response, we observed a long
duration of initial HAART (65 months). The primary reason for
first-line regimen discontinuation was poor adherence to antiret-
rovirals. This is in accordance with the results of the multivable
analysis, which indicated more than 2-fold higher likelihood of
discontinuation among individuals with non-adherence than those
with good/perfect adherence. No association was observed
between first-line discontinuation and baseline CD4 count, VL
or type of regimen.
Information on the duration of HAART in the paediatric
population worldwide is still scarce. High rates of initial HAART
change (78%) and an initial HAART duration of only 40 months
were observed among children attending a Spanish hospital [31].
In contrast, a large observational study of European children
reported that 65% remained on first-line antiretrovirals without
treatment interruption after 5 years [32]. Our results are between
these two studies with 55% of the children remaining on first-line
antiretrovirals without treatment interruption after 5 years.
Difference in the definition of regimen discontinuation and in
the characteristics of the study population, that included either
therapy-experienced or therapy-naı¨ve children, may account for
the longer initial HAART duration observed in our study. Despite
these differences, non-adherence to treatment was the main
determinant of first regimen duration like in our study [31]. As in
these previous studies, poor adherence to antiretroviral treatment
was the main determinant of the first regimen duration in our
children indicating that measures to increase the levels of
adherence to therapy in this population are required to extend
the duration of initial HAART regimen.
Figure 1. Kaplan–Meier survival curves for time spent on first vs. second vs. third HAART (A) and for time spent on first HAART by
adherence to antiretrovirals (B).
doi:10.1371/journal.pone.0096307.g001
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Additional information for the clinical management of HIV-1-
infected children and adolescents derives from a limited number of
studies that included HIV-1-infected adults. Some observational
surveys corroborate our results, showing high rates of initial
regimen discontinuation [33–35]. Concerning the duration of the
initial HAART regimen in HIV-infected adults, Chen R.Y. et al.
reported a median duration of only 1.6 years, while the successive
regimens were considerably shorter [36]. A study that included
Table 1. Risk factors for first-line HAART discontinuation among antiretroviral-naive paediatric patients.
Univariate (N = 104) Multivariable (N = 104)
N. N. of cases (%) HR (95% CI) P HR (95% CI) P
Age at HAART initiation, years
#2 45 24 (53.3) 1 1
2–12 50 28 (56.0) 0.78 (0.45–1,34) .36 0.80 (0.45–1,41) .44
.12 9 5 (55.6) 1.55 (0.59–4.10) .37 1.38 (0.50–3.81) .53
Sex
Girls 58 28 (48.3) 1 1
Boys 46 29 (63.0) 1.63 (0.97–2.75) .065 1.59 (0.89–2.83) .12
Geographical origin
Spain 73 45 (61.6) 1
Other 31 12 (38.7) 0.74 (0.39–1.40) .36
Adoption
No 82 45 (54.9) 1
Yes 22 12 (54.5) 0.79 (0.42–1.49) .46
Care
1 or 2 biological/adoptive parents 80 47 (58.8) 1
Relatives/Institution 20 10 (50.0) 0.97 (0.49–1.92) .92
Unknown 4 – n.a.
HIV-1 subtype
B 53 42 (79.2) 1 1
Other 20 5 (25.0) 0.41 (0.16–1.04) .062 0.71 (0.25–2.04) .53
Unknown 31 10 (32.3) 0.39 (0.19–0.77) .007 0.52 (0.24–1.13) .10
Baseline HIV-1 RNA log10, copies/mL 104 57 (54.8) 1.11 (0.76–1.64) .58
Baseline CD4 counta, cells/mL 104 57 (54.8) 0.98 (0.95–1.01) .22
Clinical status
A/B 86 46 (53.5) 1
C 18 11 (61.1) 0.89 (0.46–1.73) .74
PMTCT
No 80 47 (58.8) 1
Yes 24 10 (41.7) 0.66 (0.33–1.31) .23
Breastfeeding
No 61 34 (55.7) 1
Yes 27 19 (70.4) 1.62 (0.92–2.87) .10
Unknown 16 4 (25.0) 0.60 (0.21–1.70) .34
Year of HAART initiation
.2001 46 17 (37.0) 1 1
#2001 47 40 (85.1) 1.97 (1.11–3.50) .021 1.34 (0.68–2.63) .40
First-line regimenb
PI-based 77 42 (54.5) 1
NNRTI-based 26 14 (53.8) 1.33 (0.72–2.46) .36
Adherence
Good/perfect 67 29 (43.3) 1 1
Poor/intermediate 37 28 (75.7) 3.42 (2.01–5.84) ,.001 2.60 (1.44–4.70) .002
Legend: HR, hazard ratio; CI, confidence intervals; PMTCT, antiretroviral prophylaxis of HIV mother-to-child transmission; NNRTI, non-nucleoside reverse transcriptase
inhibitor; PI, protease inhibitor; n.a., not available; aper 100 cells/mL; bexcludes one patient who was treated with a triple NNRTI.
doi:10.1371/journal.pone.0096307.t001
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both treatment-experienced and treatment-naı¨ve patients reported
a similar duration of almost one year and durability was associated
with being pre-HAART therapy naı¨ve, prompt response to
HAART and PI-based initial regimen [37]. Antiretrovirals-
associated toxicity was described as important determinants of
discontinuation and short duration of the therapy [33,34,36].
Missing baseline data were a limitation in this study, as did not
allow the inclusion of all antiretroviral-naı¨ve children enrolled in
the Cohort who initiated HAART. Moreover, data on socio-
economic status or specific treatment-related toxicities were
available for a subgroup of the study population, thus we were
not able to fully capture their effect on therapy discontinuation.
Nevertheless, these missing data do not affect the overall HAART
duration estimates. Despite the exclusion of some patients from
this survey might represent a potential source of bias, it is of note
that several characteristics of included and not included patients
were comparable. Another limitation of this study is that
adherence was not included in the analyses as a time-dependent
variable. Notwithstanding these limitations, the long duration of
initial HAART represents a relevant and encouraging finding,
indicating that the likelihood that effective HAART will last a
lifetime is possible. However, enthusiasm for these findings may be
dampened by concerns for the risk of suboptimal adherence
observed in those patients who might benefit from additional
adherence strategies in routine clinical care.
Annex
Paediatric hospitals of the CoRISpES-Madrid Cohort working
group: Hospital Universitario ‘‘Doce de Octubre’’, Madrid (29
patients); Hospital Universitario ‘‘La Paz’’, Madrid (14 patients);
Hospital Universitario de Getafe, Madrid (13 patients); Hospital
Universitario ‘‘Carlos III’’, Madrid (12 patients); Hospital General
Universitario ‘‘Gregorio Maran˜o´n’’, Madrid (12 patients); Hospi-
tal Infantil Universitario ‘‘Nin˜o Jesu´s’’, Madrid (8 patients);
Hospital de Mo´stoles (7 patients); Hospital Prı´ncipe de Asturias,
Alcala´ de Henares, Madrid (6 patients); Hospital de Torrejo´n de
Ardoz, Madrid (3 patients).
Supporting Information
File S1 Supporting Information Table S1, Baseline characteris-
tics and antiretroviral therapy use among the study population.
Legend: amedian (IQR); bnumber (%); cmedian (95%CI); *C
(n = 3), G (n = 2), A1 (n = 1), F1 (n = 1); **recombinant subtypes:
CRF01_AE (n = 1), CRF02_AG (n = 10), CRF12_BF (n = 1),
CRF13_cpx (n = 1); #3TC/ddI+d4T+NFV (n = 23; 48.9%);
##AZT/ABV +3TC+KLT (n = 16; 53.3%); ‘d4T+ddI+EFV
(n = 7; 29.2%); ‘‘AZT +3TC+ABV+NVP (n = 2; 100%); ‘‘‘AZT
+3TC+ddI (n = 1; 100%). CRF, circulating recombinant form;
HAART, highly active antiretroviral therapy; MTCT, mother-to-
child transmission; PMTCT, antiretroviral prophylaxis of HIV
mother-to-child transmission; CMV, cytomegalovirus; HBV,
hepatitis B virus; NRTI, nonnucleoside/nucleotide reverse-
transcriptase inhibitor; NNRTI, nonnucleoside reverse-transcrip-
tase inhibitor; PI, protease inhibitor. Supporting Information
Table S2, Characteristics of included and not included patients.
Legend: $Fisher’s exact test (2-tailed); $$Mann-Whitney U test (2-
tailed). Supporting Information Table S3, Analysis of the cause of
discontinuation of first-line HAART according to the type of
regimen. Legend: NNRTI, nonnucleoside reverse-transcriptase
inhibitor; PI, protease inhibitor; *the underlying cause of death
was dideoxynucleoside-induced severe lactic acidosis. Supporting
Information Figure S1, Evolution of the percentage of the most
frequent antiretroviral drug over time (A) and evolution of viral
load (VL), %CD8 and %CD4 over time (B). Legend: Mean of
log10 VL (copies/mL), CD8
+ T-cell percentage and CD4+ T-cell
percentage; bars represent 2 s.e.m. EFV, efavirenz; KLT, kaletra;
NFV, nelfinavir.
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